BioInvent International AB
STO:BINV
Net Margin
BioInvent International AB
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
SE |
B
|
BioInvent International AB
STO:BINV
|
1.8B SEK |
-961%
|
|
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
303.1B USD |
8%
|
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
151.7B USD |
12%
|
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
130.7B USD |
2%
|
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
124.8B USD |
-5%
|
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
115.9B AUD |
18%
|
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
60.2B USD |
31%
|
|
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
NL |
![]() |
argenx SE
XBRU:ARGX
|
31.1B EUR |
38%
|
BioInvent International AB
Glance View
BioInvent International AB engages in the research and development of novel and immuno-modulatory antibodies for the treatment of cancer. The company is headquartered in Lund, Skane and currently employs 84 full-time employees. The company went IPO on 2001-06-12. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The firm has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on BioInvent International AB's most recent financial statements, the company has Net Margin of -960.9%.